Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients

NCT00148317 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT00148317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00148317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
November 30, 2012
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma